Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Thank you for selecting your broker
We are redirecting you to the Broker Center now
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Thank you for your submission, we hope you enjoy your experience
ALERT

FREE Webinar for FA’s and RIA’s — Reserve Your Seat Now!

Mutualfunds logo

FBDIX Franklin Biotechnology Discovery A

  • Fund
  • FBDIX
  • Price as of: Dec 01, 2016
  • $137.88
  • - $2.30
  • - 1.64%
  • Category
  • Health & Biotech Equities

FBDIX - Profile

Vitals

  • YTD Return -15.7%
  • 3 Yr Annualized Return 7.0%
  • 5 Yr Annualized Return 20.2%
  • Net Assets $1.22 B
  • Holdings in Top 10 50.4%

52 WEEK LOW AND HIGH

$137.88
$114.87
$173.49

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.99%

SALES FEES

  • Front Load 5.75%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 22.13%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$1,000

IRA

$250

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return -15.7%
  • 3 Yr Annualized Total Return 4.9%
  • 5 Yr Annualized Total Return 18.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.56%
DIVIDENDS
  • Dividend Yield 0.1%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Franklin Biotechnology Discovery Fund
  • Fund Family Name Franklin Templeton Investments
  • Inception Date Sep 15, 1997
  • Shares Outstanding N/A
  • Share Class A
  • Currency USD
  • Domiciled Country United States
  • Manager Evan S. McCulloch

Fund Description

The Franklin Biotechnology Discovery Fund Class A (FBDIX) is an actively managed fund that specializes in the health care sector. FBDIX specifically targets those biotech companies engaged in new drug development and marketing. This includes firms in genomics research, genetic engineering and gene expression therapy. Managers use a bottom-up, fundamental approach to picking biotech stocks for FBDIX’s assets and lean heavily on stocks with competitive profiles and large market opportunities for their drugs.

Fees for FBDIX are considered low. However, given its specialized nature, the fund is only suitable as a satellite position. The fund is internally managed by Franklin Advisers.

FBDIX - Performance

Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -15.7% -31.2% 7.4% 78.57% 4
1 Yr -18.4% -23.6% 18.4% 91.89% 5
3 Yr 7.0% * -7.5% 17.2% 66.67% 4
5 Yr 20.2% * 9.3% 21.9% 9.71% 1
10 Yr 11.9% * 6.1% 14.3% 16.16% 1

* Annualized


Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%) Quintile
2015 -3.0% -20.4% 13.8% 55.45% 3
2014 28.6% -5.9% 31.5% 9.09% 1
2013 57.5% 0.0% 65.2% 10.09% 1
2012 29.2% -5.3% 36.5% 6.80% 1
2011 -6.2% -15.5% 18.8% 79.41% 5

Total Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -15.7% -23.6% 7.4% 81.08% 5
1 Yr -23.1% -27.5% 16.2% 96.36% 5
3 Yr 4.9% * -14.2% 17.0% 79.63% 4
5 Yr 18.8% * 9.0% 21.9% 20.39% 1
10 Yr 11.3% * 6.1% 14.3% 29.29% 2

* Annualized


Total Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%) Quintile
2015 5.7% -16.6% 20.7% 68.81% 4
2014 40.0% -5.8% 55.3% 23.85% 2
2013 105.0% 0.0% 398.7% 12.96% 1
2012 53.9% -5.1% 475.8% 27.00% 2
2011 18.9% -10.2% 2296.2% 34.02% 2

NAV & Total Return History

FBDIX - Holdings

Filings data as of: Sep 30, 2016

Concentration Analysis

FBDIX Category Low Category High FBDIX % Rank Quintile
Net Assets 1.22 B 20.5 M 43.6 B 16.96% 3
Number of Holdings 116 31 345 8.04% 1
Net Assets in Top 10 695 M 9.55 M 20.9 B 15.18% 3
Weighting of Top 10 50.4% 21.8% 71.5% 5.36% 1

Top 10 Holdings

  1. Celgene Corp 8.85%
  2. Gilead Sciences Inc 6.96%
  3. Biogen Inc 8.01%
  4. Amgen Inc 5.62%
  5. Regeneron Pharmaceuticals Inc 3.30%
  6. Illumina Inc 2.66%
  7. Biomarin Pharmaceutical Inc 2.75%
  8. Incyte Corp 4.62%
  9. Vertex Pharmaceuticals Inc 3.07%
  10. Tesaro Inc 4.52%

Asset Allocation

Weighting Category Low Category High FBDIX % Rank Quintile
Stocks
93.22% 82.12% 103.35% 28.57% 5
Cash
4.46% 0.00% 16.35% 5.36% 1
Other
2.33% -3.35% 10.27% 4.46% 1
Convertible Bonds
0.00% 0.00% 0.38% 3.57% 4
Preferred Stocks
0.00% 0.00% 0.96% 4.46% 5
Bonds
0.00% 0.00% 1.91% 5.36% 4

Stock Sector Breakdown

Weighting Category Low Category High FBDIX % Rank Quintile
Healthcare
93.22% 13.15% 99.87% 18.75% 3
Financial Services
0.00% 0.00% 1.00% 6.25% 5
Real Estate
0.00% 0.00% 1.97% 2.68% 4
Industrials
0.00% 0.00% 13.35% 12.50% 5
Utilities
0.00% 0.00% 1.10% 1.79% 4
Technology
0.00% 0.00% 64.83% 24.11% 5
Energy
0.00% 0.00% 0.00% 0.89% 4
Communication Services
0.00% 0.00% 1.73% 1.79% 4
Consumer Defense
0.00% 0.00% 2.38% 12.50% 5
Consumer Cyclical
0.00% 0.00% 3.21% 7.14% 5
Basic Materials
0.00% 0.00% 4.92% 4.46% 4

Stock Geographic Breakdown

Weighting Category Low Category High FBDIX % Rank Quintile
US
90.51% 60.81% 99.87% 8.93% 1
Non US
2.71% 0.00% 41.10% 30.36% 5

FBDIX - Expenses

Operational Fees

FBDIX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.99% 0.10% 4.31% 56.25% 2
Management Fee 0.57% 0.08% 1.25% 16.07% 1
12b-1 Fee 0.24% 0.00% 1.00% 10.26% 1
Administrative Fee 0.15% 0.01% 0.40% 6.15% 4

Sales Fees

FBDIX Fees (% of AUM) Category Low Category High FBDIX Rank Quintile
Front Load 5.75% 3.50% 5.75% 3.85% 5
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

FBDIX Fees (% of AUM) Category Low Category High FBDIX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBDIX Fees (% of AUM) Category Low Category High FBDIX Rank Quintile
Turnover 22.13% 7.00% 249.00% 24.11% 1

FBDIX - Distributions

Dividend Yield Analysis

FBDIX Category Low Category High FBDIX % Rank Quintile
Dividend Yield 0.1% 0.01% 0.94% 51.06% 3

Dividend Distribution Analysis

FBDIX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

FBDIX Category Low Category High FBDIX % Rank Quintile
Net Income Ratio -0.56% -2.22% 1.40% 41.07% 3

Capital Gain Distribution Analysis

FBDIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

FBDIX - Managers

Evan S. McCulloch

Lead Manager

Start Date

Sep 15, 1997

Tenure

19.14

Tenure Rank

0.4%

Mr. McCulloch has been a portfolio manager of the Fund since 1997 and assumed duties of lead portfolio manager of the Fund in 2000. He has primary responsibility for the investments of the Fund. He has final authority over all aspects of the Fund's investment portfolio, including but not limited to, purchases and sales of individual securities, portfolio risk assessment, and the management of daily cash balances in accordance with anticipated cash management requirements. The degree to which he may perform these functions, and the nature of these functions, may change from time to time.


Steven Kornfeld

Manager

Start Date

Sep 15, 2015

Tenure

1.13

Tenure Rank

19.7%

Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.


Christopher Lee

Manager

Start Date

May 01, 2016

Tenure

0.5

Tenure Rank

21.8%

Christopher Lee is a vice president and research analyst with Franklin Equity Group. He covers biotechnology with a focus on oncology and emerging technologies such as genetherapy and RNA/DNA therapeutics. Prior research coverage includes the pharmaceutical, specialty pharma and medical technology sectors. Dr. Lee joined Franklin Templeton in 2015 and was previously with Capital Group. He has covered public and private healthcare companies since 2008 and began his career as a management consultant with McKinsey & Company. Dr. Lee received his M.D. from Columbia University and holds a B.S. in Molecular Biophysics & Biochemistry from Yale University.


Tenure Analysis

Category Low

0.0

Category High

19.1

Category Average

8.78

Category Mode

4.8